Evidence map›Paper›PMID 30881000›Full record

ArticleTherapeutics and clinical risk management2019

Treatment with

Stefan Borgmann, Beate Rieß, Rabea Siegmund, Guido Werner, Ingo Klare

Open access · goldAbstract read
In one paragraph

Article in Therapeutics and clinical risk management, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Long-Lasting Decrease of the Acquisition ofInternational journal of environmental research and public health · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Stefan BorgmannDepartment of Infectious Diseases and Infection Control, Ingolstadt Hospital, Ingolstadt, Germany, stefan.borgmann@klinikum-ingolstadt.de.
Beate RießDepartment of Infectious Diseases and Infection Control, Ingolstadt Hospital, Ingolstadt, Germany, stefan.borgmann@klinikum-ingolstadt.de.
Rabea SiegmundDepartment of Infectious Diseases and Infection Control, Ingolstadt Hospital, Ingolstadt, Germany, stefan.borgmann@klinikum-ingolstadt.de.
Guido WernerNational Reference Centre for Staphylococci and Enterococci, Robert Koch Institute, Wernigerode Branch, Wernigerode, Germany.
Ingo KlareNational Reference Centre for Staphylococci and Enterococci, Robert Koch Institute, Wernigerode Branch, Wernigerode, Germany.
Klinikum Ingolstadt · DERobert Koch Institute · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAccording to the WHO vancomycin-resistant PATIENTS AND

methodsRectal screening swabs were taken at admission and once per week on the early rehabilitation ward of Ingolstadt Hospital (ERWIN) but not at other wards. The number of VRE colonized patients was evaluated by using appropriate computer software (LabCentre, Hybase). The Hybase program was also used to find out the number of

resultsBetween 2013 and 2015 the number of VRE increased from 30 to 78 per year whereas in 2016 and 2017 the number declined to 51. Systematic analysis of the laboratory data revealed that this increase was driven by oligoclonal transmission of

conclusionApplication of

Indexed as

bacterial spreadcircuit model of bacterial transmissionmicrobiotaoligoclonal spreadoutbreakprobioticsvanAvanB

Identifiers

PMID30881000
PMCPMC6398405
OpenAlexW2917658987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.